Clinical trials: Transplantation
Liver Diseases, Surgery
RESTORE Declined Livers Study
This is a prospective, non-randomized, clinical trial of discarded liver transplants that have received normothermic machine perfusion (NMP), compared with standard cold preservation liver transplants.
- Conditions
- Liver Diseases, Surgery, Transplant; Failure, Liver
- Trial name
- NCT04483102
- Testing
- Declined liver in Normothermic Machine Perfusion (NMP), Standard cold preservation of liver
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT01621477
- Testing
- clofarabine, cytarabine, busulfan
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,
- Trial name
- RADIUS (NCT01883362)
- Testing
- Midostaurin, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Congenital Pediatric Disorders
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders
The purpose of this study is to determine the safety and effectiveness of Umbilical Cord Blood Transplant (UCBT) to treat the patient's disease, and to see if this treatment can decrease the incidence of GVHD.
- Trial name
- UCB (NCT00950846)
- Testing
- Busulfan, Cytoxan, Fludarabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Highly-sensitized Kidney Transplant Recipients
Role of Everolimus in Highly Sensitized Patients
A growing number of patients on the kidney transplant waiting list are broadly human leukocyte antigen (HLA) sensitized (HS). These patients are unlikely to have a compatible donor.
- Trial name
- NCT01911546
- Testing
- everolimus + low-dose tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joseph Kahwaji, MD, MPH
Liver Transplantation
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called…
- Trial name
- NCT00970073
- Testing
- Thymoglobulin 3mg total, Thymoglobulin 4.5mg total, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Cytomegalovirus Infection
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV) disease in R-D+ liver transplant patients.
- Trial name
- NCT01552369
- Testing
- Valganciclovir
- Where
- 6 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
Compare the difference in dose-normalized trough and total daily dose necessary to reach the steady state therapeutic goal after conversion from tacrolimus IR to Astagraf XL® in African American kidney transplant recipients.
- Trial name
- NCT02953873
- Testing
- Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Medical University of South Carolina
Post-Lung Transplantation
Improving Lung Transplant Outcomes With Coping Skills and Physical Activity
This study evaluates the effectiveness of a coping skills and exercise (CSTEX) intervention among post lung transplant patients aimed to reduce distress and improve functional capacity.
- Trial name
- INSPIRE-III (NCT04093869)
- Testing
- Coping Skills Training combined with Exercise (CSTEX), Standard of Care plus Education (SOC-ED)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Duke University
Inherited Metabolic Disorders (IMD)
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT03406962
- Testing
- MGTA-456
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Magenta Therapeutics, Inc.
Central Nervous System Lymphoma
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
This is a multicenter open label randomized phase II trial. Enrolled Primary Central Nervous System Lymphoma (PCNSL) patients will be stratified according to the IELSG score and randomized to receive one of the follows as primary…
- Trial name
- NCT01011920
- Testing
- Methotrexate, Ara-C, Rituximab
- Where
- 54 sites in Denmark, Germany and 3 more
- Volunteers
- 227 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
This phase II trial studies the side effects and best dose of total-body irradiation when given together with fludarabine phosphate followed by a donor peripheral stem cell transplant in treating patients with myelodysplastic…
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia
- Trial name
- NCT00397813
- Testing
- Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Pulmonary Infiltrate New
FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary infiltrates frequently complicate the care of hematopoietic stem cell transplant (HSCT) and leukemia patients. Bronchoalveolar lavage (BAL) is frequently used to evaluate new pulmonary infiltrates in this population…
- Trial name
- NCT01328873
- Testing
- Microbiological analysis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northside Hospital, Inc.
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00792142
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancy, Leukemia
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
This phase II clinical trial studies how well two donors stem cell transplant work in treating patients with high-risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- NCT01532635
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Cardiac Allograft Vasculopathy
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients.
- Trial name
- NCT01186250
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Sickle Cell Disease
Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause organ damage, stroke, and intense pain episodes.
- Trial name
- SCURT (NCT00745420)
- Testing
- Hematopoietic Stem Cell Transplantation
- Where
- 19 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma, Plasma Cell Neoplasm
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00075608
- Testing
- filgrastim, melphalan, autologous stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Lymphoma, Non-Hodgkin
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal…
- Trial name
- NCT00103610
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 32 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.